NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Dengvaxia US Pregnancy Registry

RecruitingN/A

Sponsor: Sanofi Pasteur, a Sanofi Company

Conditions: Dengue Virus Infection

Interventions: Dengue Tetravalent Vaccine, Live

Countries: Puerto Rico

The primary objective of this study is to assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women and their offspring(s) vaccinated with Dengvaxia during their pregnancy

Eligibility overview

Sex: ALL

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

The eligible population will include pregnant women of any age and their offspring(s) residing in the US and its Territories whose Dengvaxia pregnancy exposure is reported to the pregnancy registry.

Reports of Dengvaxia pregnancy exposure must contain the following information to be included in the registry:

* Sufficient evidence to confirm the case qualifies as "exposed during pregnancy";
* Vaccine name (brand or generic) is provided (i.e., including manufacturer unknown exposures).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (1)

San Juan, Puerto Rico